US Pharma MarketingRoche takes victory lap with lung cancer pill
MADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial against drugs with the same ... Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals…
MADRID — Roche’s next-gen KRAS G12C inhibitor cut the risk of death by 44% in previously treated mutant non-small cell lung cancer in a head-to-head trial against drugs with the same target from Amgen and Bristol ...
Source: Endpoints News